<div id="readability-page-1"><p>SS&amp;H Financial Advisors Inc. increased its position in shares of  Medtronic PLC (NYSE:MDT - Free Report) by 200.1% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor  owned 16,371 shares of the medical technology company's stock after purchasing an additional 10,915 shares during the quarter. SS&amp;H Financial Advisors Inc.'s holdings in Medtronic were worth $1,559,000 as of its most recent filing with the SEC.</p><ul><li>Medtronic Stock Finds Its Footing—Now It’s Gaining Momentum</li></ul><p>A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. 1248 Management LLC acquired a new stake in shares of  Medtronic in the first quarter valued at about $26,000.  Delos Wealth Advisors LLC purchased a new stake in  Medtronic during the 2nd quarter valued at about $27,000.  Twin Tree Management LP purchased a new stake in  Medtronic during the 1st quarter valued at about $29,000.  Activest Wealth Management raised its holdings in  Medtronic by 3,577.8% in the 1st quarter. Activest Wealth Management now owns 331 shares of the medical technology company's stock valued at $30,000 after acquiring an additional 322 shares during the last quarter.  Finally, GFG Capital LLC purchased a new position in  Medtronic in the 2nd quarter worth approximately $36,000. Hedge funds and other institutional investors own  82.06% of the company's stock. </p><h2>Medtronic Stock Performance</h2><p>Shares of MDT stock opened at $96.52 on Monday. The firm has a market cap of $123.74 billion, a price-to-earnings ratio of 26.02, a PEG ratio of 2.54 and a beta of 0.71. Medtronic PLC has a 1 year low of $79.29 and a 1 year high of $106.33. The stock's 50-day moving average is $97.54 and its two-hundred day moving average is $93.80. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.80 and a current ratio of 2.42. </p><ul><li>MarketBeat Week in Review – 08/18 - 08/22</li></ul><p>Medtronic (NYSE:MDT - Get Free Report) last announced its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 EPS for the quarter, beating analysts' consensus estimates of $1.31 by $0.05. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The business had revenue of $8.96 billion during the quarter, compared to analysts' expectations of $8.86 billion. During the same period in the prior year, the company earned $1.26 earnings per share. The business's revenue was up 6.6% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS.  Analysts predict that  Medtronic PLC will post 5.46 earnings per share for the current year. </p><h2>Medtronic Announces Dividend</h2><p>The company also recently declared a quarterly dividend, which will be paid on Friday, January 16th. Stockholders of record on Friday, December 26th will be given a $0.71 dividend. The ex-dividend date is Friday, December 26th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.9%. Medtronic's dividend payout ratio (DPR) is currently 76.55%. </p><h2>Wall Street Analyst Weigh In</h2><ul><li>Medtronic: The Opportunity Gets Healthier for Income Investors</li></ul><p>A number of equities research analysts have recently issued reports on the company. Weiss Ratings  restated a &#34;buy (b)&#34; rating on shares of Medtronic in a research report on Monday, December 15th. Piper Sandler  reiterated a &#34;neutral&#34; rating on shares of Medtronic in a report on Friday, November 14th. Morgan Stanley boosted their price objective on shares of Medtronic from $107.00 to $117.00 and gave the company an &#34;overweight&#34; rating in a report on Wednesday, November 19th. Barclays increased their target price on shares of Medtronic from $109.00 to $111.00 and gave the stock an &#34;overweight&#34; rating in a research note on Thursday, November 20th. Finally, Truist Financial dropped their target price on shares of Medtronic from $110.00 to $107.00 and set a &#34;hold&#34; rating for the company in a report on Thursday, December 18th. One equities research analyst  has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and twelve have issued  a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $109.94.</p><p><b>Check Out Our Latest Stock Analysis on MDT</b></p><h2>Medtronic Company Profile</h2> (Free Report)<p>Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.  </p><p>Medtronic's offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).</p><h2>Read More</h2><ul><li>Five stocks we like better than Medtronic</li><li>Do not delete, read immediately</li><li>How the Rich Retire</li><li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li><li>How Long Will $1M Last in Retirement?</li><li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU1EVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU1EVA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Medtronic Right Now?</h2><p>Before you consider Medtronic, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medtronic wasn't on the list.</p><p>While Medtronic currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>SS&H Financial Advisors Inc. increased its stake in Medtronic PLC (NYSE:MDT) by 200.1% in Q3, owning 16,371 shares valued at $1,559,000. Other institutional investors also adjusted their positions. Medtronic's stock opened at $96.52, with a market cap of $123.74 billion. The company reported Q3 earnings of $1.36 EPS, exceeding estimates, and announced a quarterly dividend of $0.71. Analysts have a consensus rating of "Moderate Buy" with a price target of $109.94.</p>

Medtronic PLC $MDT Shares Purchased by SS&H Financial Advisors Inc.